Small molecular CD4 mimics as HIV entry inhibitors

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• The human immunodeficiency virus (HIV) envelope glycoprotein gp120 is a primary target for antiviral therapies.
• CD4 mimics are designed to bind to gp120, inhibiting viral entry.
• Understanding the interaction between CD4 mimics and the Phe43 cavity of gp120 is crucial for developing potent inhibitors.

Purpose of the Study:

• To design and synthesize novel CD4 mimics targeting the Phe43 cavity of gp120.
• To evaluate the anti-HIV activity, cytotoxicity, and CD4 mimicry effects of these derivatives.
• To identify lead compounds with improved potency and safety profiles.

Main Methods:

• Chemical synthesis of CD4 mimic derivatives with modifications to the piperidine moiety.
• In vitro assays to assess anti-HIV activity.
• Cytotoxicity assays to determine the safety profile.
• Analysis of gp120 conformational changes induced by the compounds.

Main Results:

• Installation of bulky hydrophobic groups in the piperidine moiety led to significant gains in potency.
• A novel lead compound, designated 11, demonstrated potent anti-HIV activity.
• Compound 11 exhibited a higher selective index and enhanced CD4 mimicry compared to known CD4 mimics.
• Compound 11 showed lower cytotoxicity than existing CD4 mimics.

Conclusions:

• Novel CD4 mimics targeting the Phe43 cavity of gp120 can be effectively designed and synthesized.
• Compound 11 represents a promising novel lead with significant anti-HIV activity and improved safety.
• These findings contribute to the development of next-generation anti-HIV therapeutics.